Institution Directory

Clinical trials at Brigham and Women's Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

740

Shown on this page

Current sort

Stored official records

Conditions: Early Rectal Cancer, Microsatellite Stable Rectal Carcinoma, Stage I Rectal Cancer
Interventions: Balstilimab, Botensilimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer Surgery
Interventions: Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy; Procedure
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 4,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 2 more

Conditions: Genetic Disease
Interventions: Genome Informed Risk Assessment (GIRA) report; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 3 Years to 75 Years
Enrollment: 26,877 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • Tempe, Arizona • Chicago, Illinois + 7 more

Conditions: Aging, Facial Aging
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Antisynthetase Syndrome
Interventions: Descartes-08, Placebo; Drug · Other
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Orange, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more

Conditions: Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen Deprivation Therapy, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats, Prostate Adenocarcinoma, Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Cancer With Bone Metastasis, Prostate Carcinoma, Prostate Neoplasm, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes
Interventions: Placebo, fezolinetant - reference formulation; Drug
Lead sponsor: Shehzad Basaria, M.D.; Other
Eligibility: 40 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 348
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more

Conditions: Flushing, Rosacea, Rosacea, Erythematotelangiectatic
Interventions: Transaricular vagus nerve stimulation (taVNS); Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Alleviant ALV1 System, Sham-Control; Device · Other
Lead sponsor: Alleviant Medical, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 56
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more

Conditions: Cardiogenic Shock, Heart Failure, Inflammation
Interventions: Methylprednisone, Standard of Care (SOC); Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post Traumatic Stress Disorder (PTSD)
Interventions: Transcranial Magnetic Stimulation; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

About this Brigham and Women's Hospital institution page

What this page lists: ClinicalTrials.gov records that list Brigham and Women's Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Brigham and Women's Hospital

Filter and sort this campus

Stored official records

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment

Artificial Intelligence-Based Health Assessment From Face Photographs - Healthy Volunteer Study

Descartes-08 in Autoantibody Myositis

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea

Alleviant ALLAY-HF Study

CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock

Targeted Accelerated TMS for Post-Traumatic Stress Disorder

About this Brigham and Women's Hospital institution page